drugset / Trial / NCT06498622
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.
Timeline
- Start
- 2024-07-20
- Primary completion
- 2027-05-20
- Completion
- 2027-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 100 mg | Oral |
| Subject | Envafolimab | Monoclonal antibody | 300 mg | Other |